Division of Cancer Biology and Genetics, Department of Pathology and Molecular Medicine, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
Cancer Res. 2011 Feb 15;71(4):1465-73. doi: 10.1158/0008-5472.CAN-10-3757. Epub 2010 Dec 15.
Fes is a protein tyrosine kinase with cell autonomous oncogenic activities that are well established in cell culture and animal models, but its involvement in human cancer has been unclear. Abundant expression of Fes in vascular endothelial cells and myeloid cell lineages prompted us to explore roles for Fes in the tumor microenvironment. In an orthotopic mouse model of breast cancer, we found that loss of Fes in the host correlated with reductions in engrafted tumor growth rates, metastasis, and circulating tumor cells. The tumor microenvironment in Fes-deficient mice also showed reduced vascularity and fewer macrophages. In co-culture with tumor cells, Fes-deficient macrophages also poorly promoted tumor cell invasive behavior. Taken together, our observations argue that Fes inhibition might provide therapeutic benefits in breast cancer, in part by attenuating tumor-associated angiogenesis and the metastasis-promoting functions of tumor-associated macrophages.
Fes 是一种蛋白酪氨酸激酶,具有细胞自主的致癌活性,这在细胞培养和动物模型中得到了很好的证实,但它在人类癌症中的作用尚不清楚。Fes 在血管内皮细胞和髓系细胞谱系中的大量表达促使我们探索 Fes 在肿瘤微环境中的作用。在乳腺癌的原位小鼠模型中,我们发现宿主中 Fes 的缺失与植入肿瘤生长速度、转移和循环肿瘤细胞的减少相关。Fes 缺陷小鼠的肿瘤微环境也显示血管生成减少,巨噬细胞减少。与肿瘤细胞共培养时,Fes 缺陷型巨噬细胞也不能很好地促进肿瘤细胞的侵袭行为。总之,我们的观察结果表明,Fes 抑制可能在乳腺癌中提供治疗益处,部分原因是减弱了肿瘤相关血管生成和肿瘤相关巨噬细胞的促进转移功能。